IGF-1: Drugs That Distort This Test

What IGF-1 Actually Measures

IGF-1 is a 70-amino-acid peptide produced primarily by hepatocytes in response to growth hormone binding its receptor. Because GH pulses erratically throughout the day (peaking during deep sleep), a single GH blood draw is nearly useless for assessing GH status. IGF-1 solves that problem. Its half-life of 12-15 hours and stable circulating pool make it a reliable surrogate for integrated 24-hour GH secretion 1.

The test is ordered for two opposite clinical questions: is GH too high (acromegaly screening) or too low (GH deficiency evaluation)? It is also the primary monitoring biomarker for patients on GH replacement therapy or GH-releasing peptide protocols. The 2011 Endocrine Society clinical practice guideline for acromegaly specifically recommends age-adjusted IGF-1 as the initial screening test 2.

Any drug that alters hepatic GH receptor density, GH secretion itself, IGF-1 binding proteins, or liver synthetic capacity will distort the number on the lab report. The distortion is not trivial. Oral estrogen alone can cut IGF-1 by half, potentially triggering a false-positive workup for GH deficiency in a woman who produces GH normally 3.

Drugs That Falsely Lower IGF-1

Several medication classes suppress IGF-1 without reflecting a true decline in GH secretion. These false lows are clinically dangerous because they can prompt unnecessary GH stimulation testing, inappropriate GH prescriptions, or dose escalations in patients already on replacement.

Oral estrogens are the single most common cause of drug-induced IGF-1 suppression. Ethinyl estradiol in combined oral contraceptives and conjugated equine estrogens (Premarin) both undergo first-pass hepatic metabolism, directly downregulating hepatic IGF-1 gene transcription. A 2006 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that switching from oral to transdermal estradiol raised IGF-1 by 30-50% in postmenopausal women without any change in GH secretion 3. The Endocrine Society's 2011 guideline on GH replacement warns clinicians to account for oral estrogen use when interpreting IGF-1 levels 4.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) represent an emerging confounder. Weight loss itself reduces IGF-1. But GLP-1 agonists may also directly suppress hepatic IGF-1 production. Data from the STEP-1 trial (N=1,961) showed significant reductions in several hepatic biomarkers at 68 weeks 5. Separate smaller studies have documented IGF-1 reductions of 10-25% in patients on semaglutide 2.4 mg, though controlled data isolating the GLP-1 effect from weight-loss-mediated changes remain limited 6.

Glucocorticoids (prednisone, dexamethasone, hydrocortisone) chronically suppress IGF-1 through multiple mechanisms: reduced GH secretion via hypothalamic feedback, direct hepatic inhibition of IGF-1 synthesis, and increased IGFBP-1 production that sequesters free IGF-1. Patients on prednisone ≥7.5 mg/day for more than 3 months commonly show IGF-1 levels 20-40% below age-matched norms 7.

Tamoxifen and raloxifene (selective estrogen receptor modulators) behave like oral estrogens at the liver, suppressing IGF-1 by approximately 20-30%. A randomized trial published in the Journal of the National Cancer Institute found that tamoxifen 20 mg/day reduced IGF-1 by 28% over 3 months 8.

Drugs That Falsely Raise IGF-1

False elevations create the opposite diagnostic trap: a patient looks acromegalic on paper but has no pituitary adenoma. They also complicate dosing decisions for clinicians titrating GH peptide protocols who rely on IGF-1 to gauge response.

Exogenous growth hormone (somatropin, lonapegsomatropin) predictably raises IGF-1. That is its intended pharmacologic effect. The distortion problem arises when a patient does not disclose GH use, or when a clinician forgets to account for the dose-response lag. IGF-1 reaches a new steady state 4-6 weeks after a GH dose change, per the Endocrine Society's 2011 adult GH deficiency guideline 4. Drawing IGF-1 at 2 weeks post-dose-change will underestimate the eventual peak.

GH-releasing peptides and secretagogues (sermorelin, tesamorelin, ipamorelin, CJC-1295) stimulate endogenous GH release, which then raises IGF-1. Tesamorelin, FDA-approved for HIV-associated lipodystrophy, increased IGF-1 by a mean of 81% (from 135 to 244 ng/mL) in its key trial (N=412) 9. Compounded peptide combinations (e.g., ipamorelin/CJC-1295) produce variable but real IGF-1 elevations that must be declared before any diagnostic IGF-1 draw.

Testosterone and anabolic steroids increase IGF-1 through two pathways: direct hepatic stimulation and indirect GH augmentation via increased sleep quality and lean mass. A 2004 study in testosterone-replaced hypogonadal men showed a 15-25% rise in IGF-1 at 6 months 10. Supraphysiologic doses used in bodybuilding contexts push IGF-1 considerably higher.

Insulin (both endogenous hyperinsulinemia and exogenous injections) upregulates hepatic GH receptor expression. Patients with type 2 diabetes and significant insulin resistance may have IGF-1 levels at the upper end of normal despite no increase in GH secretion. Conversely, patients with type 1 diabetes who are under-insulinized sometimes show low IGF-1 because hepatic GH receptor activity depends on portal insulin concentrations 11.

MK-677 (ibutamoren), an oral GH secretagogue sometimes sold as a research chemical, consistently raises IGF-1 by 40-90% within weeks. A 2-year randomized trial in healthy older adults (N=65) demonstrated a sustained 50% increase in IGF-1 with MK-677 25 mg/day 12.

How Nutritional Status and Body Composition Confound the Picture

Drugs do not act in isolation. The liver needs adequate protein, calories, and thyroid hormone to produce IGF-1. Any drug that secondarily impairs nutritional intake (think chemotherapy-induced nausea, high-dose topiramate, or stimulant medications that suppress appetite) may lower IGF-1 without a primary hepatic mechanism.

Caloric restriction alone drops IGF-1 substantially. A study of 218 adults on 25% caloric restriction over 2 years (CALERIE trial) showed a 21% reduction in IGF-1 from baseline 13. Patients taking semaglutide, phentermine-topiramate, or any weight-loss medication who eat significantly fewer calories will show IGF-1 reductions that blend pharmacologic and nutritional effects. Separating these two causes clinically is often impossible without a washout period.

Hypothyroidism independently suppresses IGF-1. Patients started on levothyroxine often see IGF-1 rise as thyroid function normalizes. Clinicians ordering IGF-1 should confirm TSH is within range before attributing a low IGF-1 to GH deficiency or a medication effect 14.

Obesity raises IGF-1 mildly in some individuals while paradoxically suppressing GH secretion. This discordance confuses interpretation. The mechanism involves higher portal insulin levels driving hepatic GH receptor upregulation, compensating for reduced GH pulses 11.

The Clinical Decision: Hold, Switch, or Flag

The right approach depends on why the IGF-1 was ordered.

For acromegaly screening, the Endocrine Society recommends measuring IGF-1 regardless of medications but interpreting results in the context of oral estrogen or other suppressors 2. A normal IGF-1 in a patient on oral estrogen does not exclude acromegaly. The guideline suggests proceeding to oral glucose tolerance test (OGTT) with GH nadir if clinical suspicion is high, even with a "normal" IGF-1.

For GH deficiency evaluation, oral estrogen should ideally be switched to transdermal before testing. The Endocrine Society's 2011 adult GH deficiency guideline states: "Oral estrogen administration lowers serum IGF-1 and may lead to a false diagnosis of GHD. If feasible, switching to transdermal estrogen for at least 4 weeks before retesting is recommended" 4.

For GH or peptide therapy monitoring, the goal is to see the drug effect on IGF-1, so the medication stays on. But other confounders (oral estrogens, glucocorticoids, caloric restriction) should be documented. A patient on sermorelin whose IGF-1 is not rising may not be a peptide non-responder. She may be on oral contraceptives that mask the response.

Practical hold times before diagnostic IGF-1 testing:

• Oral estrogens: switch to transdermal for 4-6 weeks
• GH or GH peptides: discontinue for 2-4 weeks (somatropin) or 1-2 weeks (short-acting peptides like ipamorelin)
• Glucocorticoids: taper and hold for 4-6 weeks when medically safe
• Testosterone: no standard hold recommendation; document dose and draw timing
• MK-677: hold for 2-4 weeks
• GLP-1 agonists: no formal guideline yet; document use and interpret cautiously

How to Lower IGF-1

Patients with elevated IGF-1 (whether from acromegaly, exogenous GH, or peptide therapy) may need pharmacologic or lifestyle interventions to bring levels down. The primary medical treatments target the GH-IGF-1 axis directly.

Somatostatin analogs (octreotide LAR, lanreotide) suppress both GH and IGF-1. Octreotide LAR normalized IGF-1 in approximately 65% of acromegaly patients in the key registration trials 15. Pegvisomant, a GH receptor antagonist, blocks IGF-1 production at the hepatic level and normalized IGF-1 in 97% of patients in its phase III trial 16.

For patients not treating acromegaly but seeking to lower IGF-1 for longevity purposes: reducing protein intake (specifically animal protein), caloric restriction, and discontinuing any GH or peptide supplementation are the evidence-backed strategies. The CALERIE data showing 21% IGF-1 reduction with moderate caloric restriction remain the strongest human evidence 13.

How to Raise IGF-1

Low IGF-1 from genuine GH deficiency is treated with recombinant GH replacement. The Endocrine Society recommends starting somatropin at 0.1-0.2 mg/day in adults, titrating every 4-6 weeks to an IGF-1 target in the mid-normal range for age 4.

Reversible causes of low IGF-1 should be corrected first. Fix hypothyroidism (normalize TSH). Address malnutrition or severe caloric deficit. Switch oral estrogen to transdermal. Taper glucocorticoids if possible. Ensure adequate sleep, since most GH secretion occurs during slow-wave sleep, and both sleep deprivation and untreated obstructive sleep apnea reduce GH output 17.

Exercise, particularly high-intensity resistance training, acutely raises GH secretion and may modestly raise IGF-1 over months. However, the effect size is small (5-15%) and inconsistent across studies 18.

Normal IGF-1 Range by Age

IGF-1 peaks during puberty (roughly 200-900 ng/mL at ages 14-16) and declines steadily thereafter. Approximate reference ranges for adults, based on Mayo Clinic and Quest Diagnostics assays, are:

• Ages 20-30: 115-355 ng/mL
• Ages 30-40: 100-307 ng/mL
• Ages 40-50: 90-260 ng/mL
• Ages 50-60: 71-234 ng/mL
• Ages 60-70: 60-210 ng/mL
• Ages 70-80: 50-187 ng/mL

These ranges are assay-dependent. Different immunoassays (Siemens Immulite, DiaSorin Liaison, LC-MS/MS) produce different absolute values. The Endocrine Society recommends using the same assay for serial monitoring and interpreting results only against that assay's age- and sex-specific reference range 2.

A single IGF-1 value means little without clinical context. A 45-year-old woman on oral estrogen and semaglutide with an IGF-1 of 72 ng/mL is not necessarily GH-deficient. She may be experiencing predictable pharmacologic suppression from two separate drug classes. Document the medication list. Retest after addressing confounders.